EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Co-culturing hiPSC-cardiomyocytes and cardiac fibroblasts enhances engineered heart tissue structure and function

Yinhan Luo, Jeremy Parker, Armando Alcázar Magaña, Ardin Sacayanan, Kate Huang, Ian Fernandes, Gordon M Keller, Peter H Backx, Leonard J Foster, Zachary Laksman

Stem Cells Translational Medicine · 2026-05-18 · 15 (7)

DOI: 10.1093/stcltm/szag041 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Engineered heart tissues (EHTs) are widely used for cardiac disease modeling and drug screening, but their lack of multicellularity limits translational relevance. Thus, it is essential to incorporate other cardiac cells to improve the reliability and accuracy of the model. Objectives To develop a co-culture EHT model from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) and cardiac fibroblasts (CFs) and assess its structural, contractile, electrophysiological and metabolic properties. Methods hiPSCs were differentiated into CMs and CFs and combined at a ratio of 3:1 to generate co-culture EHTs. Structural, functional and metabolic features of CM-only and co-culture EHTs were evaluated and compared using immunofluorescence, force analysis, optical mapping and metabolomics. Results Co-culture EHTs were more compact, generated higher force when stimulated, and displayed improved sarcomere organization compared to CM-only EHTs. They showed reduced hypoxia under high frequency pacing and a more mature, stress resistant metabolic profile, while maintaining stable electrophysiology and reduced arrhythmogenicity. Conclusions Incorporating hiPSC-CFs into EHTs enhanced structural and functional properties, improved stress resistance, and reduced variability, making our co-culture EHTs a more physiological and predictive platform for cardiac disease modeling and drug screening.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →